A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

Ascendis Pharma

Status and phase: Completed; Phase 3

Conditions: Pituitary Diseases; hGH (Human Growth Hormone); Hormones; Growth Hormone Deficiency, Pediatric; Endocrine System Diseases

Treatments: Drug: Once weekly subcutaneous injection of TransCon hGH; Drug: Once daily subcutaneous injection of Genotropin

Study type: Interventional

Funder types: Industry

Identifiers

NCT02781727

TransCon hGH CT-301

2016-001145-11 (EudraCT Number)

Details and patient eligibility

About

A 52 week trial of TransCon hGH, a long-acting growth hormone product, versus human growth hormone therapy. TransCon hGH will be given once-a-week, human growth hormone (hGH) will be given daily. Approximately 150 prepubertal, hGH-treatment naïve children (males and females) with GHD will be included. Randomization will occur in a 2:1 ratio (TransCon hGH : Genotropin). This is a global trial that will be conducted in Armenia, Australia, Belarus, Bulgaria, Georgia, Greece, Italy, New Zealand, Poland, Romania, Russia, Turkey, Ukraine, and the United States.

Enrollment: 162 patients

Sex: All

Ages: 3 to 12 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Prepubertal children with GHD (either isolated or as part of a multiple pituitary hormone deficiency) in Tanner stage 1 (Tanner 1982) aged:

  • Boys: 3-12 years, inclusive
  • Girls: 3-11 years, inclusive

• Impaired height (HT) defined as at least 2.0 standard deviations (SD) below the mean height for chronological age and sex (HT SDS ≤ -2.0) according to the 2000 CDC Growth Charts for the United States Methods and Development, available at http://www.cdc.gov/growthcharts/

• Diagnosis of GHD confirmed by 2 different GH stimulation tests, defined as a peak GH level of ≤10 ng/mL, determined with a validated assay

• Bone age (BA) at least 6 months less than chronological age

• Baseline IGF-1 level of at least 1 SD below the mean IGF-1 level standardized for age and sex (IGF-1 SDS ≤-1)

• Written, signed informed consent of the parent(s) or legal guardian(s) of the subject and written assent of the subject (if the subject is able to read, understand, and sign)

Exclusion criteria

• Children with a body weight below 12 kg
• Prior exposure to recombinant hGH or IGF-1 therapy
• Children with past or present intracranial tumor growth as confirmed by a sellar MRI scan (with contrast) at Screening (MRI results from up to 6 months prior to Screening may be accepted)
• Children with psychosocial dwarfism
• Children with idiopathic short stature
• History or presence of malignant disease; any evidence of present tumor growth
• Closed epiphyses
• Major medical conditions and/or presence of contraindication to hGH treatment
• Participation in any other trial of an investigational agent within 3 months prior to Screening

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

162 participants in 2 patient groups

TransCon hGH

Experimental group

Description:

Once weekly subcutaneous injection of TransCon hGH

Treatment:

Drug: Once weekly subcutaneous injection of TransCon hGH

human growth hormone (Genotropin)

Active Comparator group

Description:

Once daily subcutaneous injection of Genotropin

Treatment:

Drug: Once daily subcutaneous injection of Genotropin